In November 2026, Swiss Re reported that Life & Health Reinsurance net income rose 43% to US$1.5 billion in the first nine months of the year, with US mortality experience remaining favourable. The release appeared on 5 November and covered the period ended 30 September. The nine-month result describes a reinsurance segment with multiple lines and markets. It is a useful signal for buyers of protection, but it cannot establish the renewal price or claims outlook of a particular employer’s group life programme.
What favourable mortality can mean
In a protection portfolio, fewer or less costly death claims than expected can improve experience relative to assumptions. The comparison depends on the insured population, sums at risk and how those assumptions were set. A favourable result over nine months does not establish that the underlying trend will continue, and a comparison for one geography need not apply to another. Neither does the earnings figure isolate the contribution of mortality from all other influences on the segment.
An employer generally sees a narrower pool than a global reinsurer. A relatively small number of large claims can dominate results in a given year. A comparison across countries can also be affected by different benefit formulas, workforce ages and occupations, coverage limits or changes in headcount. The relevant question is whether changes in losses are consistent with changes in exposure, or whether the result reflects a different mix of risks or ordinary volatility.
Ask for an explanation that matches the portfolio
For a renewal or pooling review, request a consistent view of covered lives, sums insured, premiums and claims by market, with a clear split between paid and incurred amounts. Ask how incomplete claim reporting and large claims affect the comparison. The employer can then distinguish changes in experience from changes in terms, reporting or insured payroll. Where a local scheme is small, ask which wider benchmark informs the price and whether its population and benefits are comparable.
A buyer also needs to know how the result reaches its own contract. A local insurer may price and administer benefits, while a pool or reinsurer assumes only part of the exposure. The participant’s eligibility, exclusions and claims process are determined by the applicable policy. The segment disclosure does not say what capacity any local insurer will offer, whether rates will fall or whether the terms of a multinational arrangement will change.
Keep the counterparty review separate from rate negotiations
The earnings announcement is one input into a counterparty review. A board can ask about the financial strength and role of each legal entity in the chain, the programme’s exposure to concentrations and the options available if a provider changes appetite. It should also know who would be responsible for outstanding claims if the employer changes provider. Underwriting performance and the continuity of benefit payments are related concerns, but they require different information.
For a captive that takes a share of employee life risk, independent non-executive directors should ask management to explain how a favourable period affects the evidence behind pricing and reserves, including whether the result survives a scenario with several large claims. They should check that the reinsurance limits and retained amounts still fit the board’s appetite for volatility.
The same discipline applies to the experience period. Compare exposures and claims over consistent dates, and identify whether recent claims are still developing. A favourable year should prompt a question about the underlying data before it changes a funding decision.
Swiss Re’s disclosure gives global benefits teams a reason to revisit mortality experience and the capacity behind their programmes. The practical next step is to compare the carrier signal with the employer’s own exposures and local terms. A renewal decision is stronger when it shows which changes in price reflect actual claims experience, which reflect contract design and which reflect the insurer’s broader view of risk.
Sources
Swiss Re ad hoc release | Nine months ended 30 Sep 2026 – Swiss Re life and health profit rises 43% on favourable US mortality
Share this:
- More [2]
